324 related articles for article (PubMed ID: 33260316)
1. Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence.
Pandey K; Park N; Park KS; Hur J; Cho YB; Kang M; An HJ; Kim S; Hwang S; Moon YW
Cancers (Basel); 2020 Nov; 12(12):. PubMed ID: 33260316
[TBL] [Abstract][Full Text] [Related]
2. Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer.
Katuwal NB; Kang MS; Ghosh M; Hong SD; Jeong YG; Park SM; Kim SG; Sohn J; Kim TH; Moon YW
J Exp Clin Cancer Res; 2023 Nov; 42(1):325. PubMed ID: 38017459
[TBL] [Abstract][Full Text] [Related]
3. Dual Inhibition of CDK4 and CDK2 via Targeting p27 Tyrosine Phosphorylation Induces a Potent and Durable Response in Breast Cancer Cells.
Patel P; Tsiperson V; Gottesman SRS; Somma J; Blain SW
Mol Cancer Res; 2018 Mar; 16(3):361-377. PubMed ID: 29330290
[TBL] [Abstract][Full Text] [Related]
4. Combination of Abemaciclib following Eribulin Overcomes Palbociclib-Resistant Breast Cancer by Inhibiting the G2/M Cell Cycle Phase.
Pandey K; Katuwal NB; Park N; Hur J; Cho YB; Kim SK; Lee SA; Kim I; Lee SR; Moon YW
Cancers (Basel); 2022 Jan; 14(1):. PubMed ID: 35008374
[TBL] [Abstract][Full Text] [Related]
5. Effects of CDK4/6 Inhibition in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Cells with Acquired Resistance to Paclitaxel.
Trapé AP; Liu S; Cortes AC; Ueno NT; Gonzalez-Angulo AM
J Cancer; 2016; 7(8):947-56. PubMed ID: 27313785
[TBL] [Abstract][Full Text] [Related]
6. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
[TBL] [Abstract][Full Text] [Related]
7. Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor.
Freeman-Cook K; Hoffman RL; Miller N; Almaden J; Chionis J; Zhang Q; Eisele K; Liu C; Zhang C; Huser N; Nguyen L; Costa-Jones C; Niessen S; Carelli J; Lapek J; Weinrich SL; Wei P; McMillan E; Wilson E; Wang TS; McTigue M; Ferre RA; He YA; Ninkovic S; Behenna D; Tran KT; Sutton S; Nagata A; Ornelas MA; Kephart SE; Zehnder LR; Murray B; Xu M; Solowiej JE; Visswanathan R; Boras B; Looper D; Lee N; Bienkowska JR; Zhu Z; Kan Z; Ding Y; Mu XJ; Oderup C; Salek-Ardakani S; White MA; VanArsdale T; Dann SG
Cancer Cell; 2021 Oct; 39(10):1404-1421.e11. PubMed ID: 34520734
[TBL] [Abstract][Full Text] [Related]
8. LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer.
Jin X; Ge LP; Li DQ; Shao ZM; Di GH; Xu XE; Jiang YZ
Mol Cancer; 2020 May; 19(1):87. PubMed ID: 32393270
[TBL] [Abstract][Full Text] [Related]
9. Indisulam synergizes with palbociclib to induce senescence through inhibition of CDK2 kinase activity.
Pogacar Z; Johnson JL; Krenning L; De Conti G; Jochems F; Lieftink C; Velds A; Wardak L; Groot K; Schepers A; Wang L; Song JY; van de Ven M; van Tellingen O; Medema RH; Beijersbergen RL; Bernards R; Leite de Oliveira R
PLoS One; 2022; 17(9):e0273182. PubMed ID: 36067171
[TBL] [Abstract][Full Text] [Related]
10. Overexpressed Cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4/6 inhibitor in breast cancer that can be reversed by PI3K/mTOR inhibitors.
Cai Z; Wang J; Li Y; Shi Q; Jin L; Li S; Zhu M; Wang Q; Wong LL; Yang W; Lai H; Gong C; Yao Y; Liu Y; Zhang J; Yao H; Liu Q
Sci China Life Sci; 2023 Jan; 66(1):94-109. PubMed ID: 35982377
[TBL] [Abstract][Full Text] [Related]
11. 4-Acetylantroquinonol B induced DNA damage response signaling and apoptosis via suppressing CDK2/CDK4 expression in triple negative breast cancer cells.
Satriyo PB; Su CM; Ong JR; Huang WC; Fong IH; Lin CC; Aryandono T; Haryana SM; Deng L; Huang CC; Tzeng YM; Chao TY; Liu HW; Yeh CT
Toxicol Appl Pharmacol; 2021 Jul; 422():115493. PubMed ID: 33727089
[TBL] [Abstract][Full Text] [Related]
12. Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer.
Jansen VM; Bhola NE; Bauer JA; Formisano L; Lee KM; Hutchinson KE; Witkiewicz AK; Moore PD; Estrada MV; Sánchez V; Ericsson PG; Sanders ME; Pohlmann PR; Pishvaian MJ; Riddle DA; Dugger TC; Wei W; Knudsen ES; Arteaga CL
Cancer Res; 2017 May; 77(9):2488-2499. PubMed ID: 28249908
[TBL] [Abstract][Full Text] [Related]
13. Deregulated Immune Pathway Associated with Palbociclib Resistance in Preclinical Breast Cancer Models: Integrative Genomics and Transcriptomics.
Pandey K; Lee E; Park N; Hur J; Cho YB; Katuwal NB; Kim SK; Lee SA; Kim I; An HJ; Hwang S; Moon YW
Genes (Basel); 2021 Jan; 12(2):. PubMed ID: 33504001
[TBL] [Abstract][Full Text] [Related]
14. CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2- Metastatic Breast Cancer.
Guerrero-Zotano Á; Belli S; Zielinski C; Gil-Gil M; Fernandez-Serra A; Ruiz-Borrego M; Ciruelos Gil EM; Pascual J; Muñoz-Mateu M; Bermejo B; Margeli Vila M; Antón A; Murillo L; Nissenbaum B; Liu Y; Herranz J; Fernández-García D; Caballero R; López-Guerrero JA; Bianco R; Formisano L; Turner N; Martín M
Clin Cancer Res; 2023 Apr; 29(8):1557-1568. PubMed ID: 36749874
[TBL] [Abstract][Full Text] [Related]
15. Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma.
AbuHammad S; Cullinane C; Martin C; Bacolas Z; Ward T; Chen H; Slater A; Ardley K; Kirby L; Chan KT; Brajanovski N; Smith LK; Rao AD; Lelliott EJ; Kleinschmidt M; Vergara IA; Papenfuss AT; Lau P; Ghosh P; Haupt S; Haupt Y; Sanij E; Poortinga G; Pearson RB; Falk H; Curtis DJ; Stupple P; Devlin M; Street I; Davies MA; McArthur GA; Sheppard KE
Proc Natl Acad Sci U S A; 2019 Sep; 116(36):17990-18000. PubMed ID: 31439820
[TBL] [Abstract][Full Text] [Related]
16. INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors.
Dietrich C; Trub A; Ahn A; Taylor M; Ambani K; Chan KT; Lu KH; Mahendra CA; Blyth C; Coulson R; Ramm S; Watt AC; Matsa SK; Bisi J; Strum J; Roberts P; Goel S
Cancer Discov; 2024 Mar; 14(3):446-467. PubMed ID: 38047585
[TBL] [Abstract][Full Text] [Related]
17. Nifuroxazide boosts the anticancer efficacy of palbociclib-induced senescence by dual inhibition of STAT3 and CDK2 in triple-negative breast cancer.
Wang X; Shi W; Wang X; Lu JJ; He P; Zhang H; Chen X
Cell Death Discov; 2023 Sep; 9(1):355. PubMed ID: 37752122
[TBL] [Abstract][Full Text] [Related]
18. Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer.
Al-Qasem AJ; Alves CL; Ehmsen S; Tuttolomondo M; Terp MG; Johansen LE; Vever H; Hoeg LVA; Elias D; Bak M; Ditzel HJ
NPJ Precis Oncol; 2022 Sep; 6(1):68. PubMed ID: 36153348
[TBL] [Abstract][Full Text] [Related]
19. Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor?
Xi J; Ma CX
Curr Oncol Rep; 2020 May; 22(6):57. PubMed ID: 32415339
[TBL] [Abstract][Full Text] [Related]
20. Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER+ Breast Cancers.
Soosainathan A; Iravani M; El-Botty R; Alexander J; Sourd L; Morisset L; Painsec P; Orha R; Nikitorowicz-Buniak J; Pancholi S; Haider S; Dowsett M; Marangoni E; Martin LA; Isacke CM
Cancer Res; 2024 Jan; 84(1):17-25. PubMed ID: 37801608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
